Kliniken Suedostbayern AG — Clinical Trial Site

17 Registered trials

9 Currently recruiting

Organisation

Kliniken Suedostbayern AG

Location

Traunstein, Germany

Identifier

ORG-100029510

Address

Cuno-Niggl-Strasse 3, 83278, Germany

Departments

Abteilung für Hämatologie und Onkologie
Department for Hematology, Oncology and Palliative Medicine
Department of Neurology
Haematologie/Onkologie/Palliativmedizin
Hämatologie - Onkologie - Palliativmedizin
Hämatologie-Onkologie
Hämatologie-Onkologie-Palliativmedizin
Hämatologie-Onkologie-Palliativmedizin Klinikum Traunstein
Hämatologie, Onkologie
Hematology - Oncology - Palliative medicine
Hematology-oncology-palliative care
Innere Medizin, Abteilung Hämato-Onkologie
Kliniken Südostbayern AG - Klinikum Traunstein - Hämatologie, Onkologie
Klinikum Traunstein Hämatologie-Onkologie-Palliativmedizin
Medizinische Abteilung 5/3 Hämatologie
Onkologie – Hämatologie

Clinical trials at this site (17)

Search interface

Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous system Pending

2025-523654-13-00 Demyelinating diseases 10
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Recruiting

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5 2026-06-01
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Ended

2022-500453-16-00 Multiple Myeloma 4 2023-10-30
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended

2023-509859-13-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-11-09
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Ended

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15